Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Stock Analysis & Ratings

SRRK Stock Chart & Stats

Day’s Range$4.84 - $5.32
52-Week Range$4.84 - $44.95
Previous Close$5.1
Average Volume (3M)397.59K
Market Cap$186.75M
P/E Ratio-1.5
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)-3.64



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $4.84 and its highest was $44.95 in the past 12 months.
    What is Scholar Rock Holding’s market cap?
    Scholar Rock Holding’s market cap is $186.75M.
      What is Scholar Rock Holding’s price target?
      The average price target for Scholar Rock Holding is $35.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $55.00 ,the lowest forecast is $24.00. The average price target represents 574.29% Increase from the current price of $5.29.
        What do analysts say about Scholar Rock Holding?
        Scholar Rock Holding’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Scholar Rock Holding’s upcoming earnings report date?
          Scholar Rock Holding’s upcoming earnings report date is Aug 11, 2022 which is in 82 days.
            How were Scholar Rock Holding’s earnings last quarter?
            Scholar Rock Holding released its earnings results on May 16, 2022. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.36.
              Is Scholar Rock Holding overvalued?
              According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
                Does Scholar Rock Holding pay dividends?
                Scholar Rock Holding does not currently pay dividends.
                What is Scholar Rock Holding’s EPS estimate?
                Scholar Rock Holding’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Scholar Rock Holding have?
                Scholar Rock Holding has 35,300,000 shares outstanding.
                  What happened to Scholar Rock Holding’s price movement after its last earnings report?
                  Scholar Rock Holding reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went up 14.971%.
                    Which hedge fund is a major shareholder of Scholar Rock Holding?
                    Among the largest hedge funds holding Scholar Rock Holding’s share is Graham Capital Management, L.P.. It holds Scholar Rock Holding’s shares valued at 321K.


                      Scholar Rock Holding Stock Analysis

                      Smart Score
                      Price Target
                      ▲(574.29% Upside)
                      Strong Buy
                      The Scholar Rock Holding stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Scholar Rock Holding Corp

                      Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      Kiniksa Pharmaceuticals
                      Magenta Therapeutics
                      Replimune Group
                      Homology Medicines

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis